A- A A+

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE). 

Schulte B, Lehmann K, Schmidt CS, Rühling E, Weber B, Schäfer I, Reimer J, Verthein U. 

Front Psychiatry. 2020 Dec 8;11:580863. doi: 10.3389/fpsyt.2020.580863. PMID: 33363483; PMCID: PMC7752950.


Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction. 

Marwah R, Coons C, Myers J, Dumont Z. 

Can Fam Physician. 2020 Dec;66(12):891-894. French. doi: 10.46747/cfp.6612891. Erratum in: Can Fam Physician. 2020 Dec;66(12):e302-e306. PMID: 33334955; PMCID: PMC7745932.


Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users. 

Mariani JJ, Mahony A, Iqbal MN, Luo SX, Naqvi NH, Levin FR.

Am J Addict. 2020 Jul;29(4):345-348. doi: 10.1111/ajad.13018. Epub 2020 Mar 13. PMID: 32167629; PMCID: PMC7383940.


Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. 

Randhawa PA, Brar R, Nolan S. 

CMAJ. 2020 Jan 20;192(3):E73. doi: 10.1503/cmaj.74018. PMID: 31959660; PMCID: PMC6970598.


Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. 

Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P. 

Addict Sci Clin Pract. 2020 Jan 15;15(1):2. doi: 10.1186/s13722-020-0177-x. PMID: 31941547; PMCID: PMC6964069.


A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. 

Seguí HA, Melin K, Quiñones DS, Duconge J. 

J Transl Genet Genom. 2020;4:263-277. doi: 10.20517/jtgg.2020.35. Epub 2020 Jul 30. PMID: 33274315; PMCID: PMC7709797.


Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine. 

Parsons G, Ragbir C, D'Agnone O, Gibbs A, Littlewood R, Hard B. 

Subst Abuse Rehabil. 2020 Nov 2;11:41-47. doi: 10.2147/SAR.S266838. PMID: 33173372; PMCID: PMC7648142.


Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.

Martin A, Butler K, Chavez T, Herring A, Wakeman S, Hayes BD, Raja A.

West J Emerg Med. 2020 Nov 2;21(6):257-263. doi: 10.5811/westjem.2020.7.46079. PMID: 33207174; PMCID: PMC7673896.


Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders. 

Bestepe EE, Tunali N, Sarıdoğan GE. 

Neuropsychiatr Dis Treat. 2020 Nov 12;16:2695-2705. doi: 10.2147/NDT.S276708. PMID: 33209025; PMCID: PMC7669501.


Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. 

Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V, Johnson C, Learned SM, Mehra V, Heidbreder C.

J Addict Med. 2020 Sep/Oct;14(5):e233-e240. doi: 10.1097/ADM.0000000000000647. PMID: 32187112; PMCID: PMC7547872.


How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder?

Evidence has mounted regarding the short-term effectiveness of long-acting buprenorphine formulations for opioid use disorder, but knowledge about longer-term psychosocial and other health outcomes have been lacking. This paper reports 12-month outcomes from a study of individuals who had previously taken part in one of two, year-long, clinical trials of a long-acting, injectable formulation of buprenorphine for moderate to severe opioid use disorder. (RRI – Recovery Research Institute, USA, November 2020)


Reconsidering the Usefulness of Adding Naloxone to Buprenorphine. 

Blazes CK, Morrow JD. 

Front Psychiatry. 2020 Sep 11;11:549272. doi: 10.3389/fpsyt.2020.549272. PMID: 33061915; PMCID: PMC7517938.


Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. 

Tran PN, Sheng J, Randolph AL, Baron CA, Thiebaud N, Ren M, et al. (2020) 

PLoS ONE 15(11): e0241362. doi.org/10.1371/journal.pone.0241362


Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions. 

Cao SS, Dunham SI, Simpson SA. 

Open Access Emerg Med. 2020 Oct 14;12:261-274. doi: 10.2147/OAEM.S267416. PMID: 33116962; PMCID: PMC7569244.


Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017. 

Rhee TG, D'Onofrio G, Fiellin DA. 

JAMA Netw Open. 2020 Oct 1;3(10):e2021209. doi: 10.1001/jamanetworkopen.2020.21209. PMID: 33079195; PMCID: PMC7576404.


Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.

Lapeyre-Mestre M. 

Therapie. 2020 Sep-Oct;75(5):393-395. doi: 10.1016/j.therap.2020.09.007. Epub 2020 Sep 28. PMID: 33039103; PMCID: PMC7521403.


Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report. 

Szczesniak, L.M., Calleo, V.J. & Sullivan, R.W. 

Harm Reduct J 17, 71 (2020). doi.org/10.1186/s12954-020-00417-9


'Game-changer' drug to tackle addiction

For more than 20 years, Dougie's life was a vicious cycle of drugs, crime and the death of people close to him. But for the past nine months he has been taking a medication that blocks his craving for heroin and helps him break the cycle. 

…he has been prescribed Buvidal, a new development in the treatment of addiction to opiates. (BBC, UK, 15.10.2020)


A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales. 

Gibson, R., MacLeod, N., Donaldson, L. J., Williams, H., Hibbert, P., Parry, G., Bhatt, J., Sheikh, A., and Carson‐Stevens, A. (2020) 

Addiction, 115: 2066– 2076. doi.org/10.1111/add.15039.


Should Buprenorphine Induction Dosing Be Lower for the Elderly Population With Opioid Use Disorder? A Case of Buprenorphine-Induced Hemodynamic Instability. 

Chaparro A, Ravishankar DA, Sethi R. 

Prim Care Companion CNS Disord. 2020 Sep 10;22(5):19l02514. doi: 10.4088/PCC.19l02514. PMID: 32910846.


Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. 

Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, Platt RW, Siebert U, Socías ME, Tsui JI, Wood E, Nosyk B. 

BMJ Open. 2020 Sep 9;10(9):e036102. doi: 10.1136/bmjopen-2019-036102. PMID: 32912944; PMCID: PMC7482450.


Buprenorphine Implants, Injections Are Underused. 

Rubin R. 

JAMA. 2020 Sep 22;324(12):1128. doi: 10.1001/jama.2020.17587. PMID: 32960225.


Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review. 

LeSaint KT, Klapthor B, Wang RC, Geier C. 

West J Emerg Med. 2020 Aug 24;21(5):1175-1181. doi: 10.5811/westjem.2020.6.46452. PMID: 32970572; PMCID: PMC7514395.


OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. 

Wright N, Hard J, Fearns C, Gilman M, Littlewood R, Clegg R, Parimelalagan L, Alam F. 

Clinicoecon Outcomes Res. 2020;12:499-504, doi.org/10.2147/CEOR.S256714


Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. 

Tompkins CNE, Neale J, Strang J. J Subst Abuse Treat. 2019;104:64-71. doi:10.1016/j.jsat.2019.06.007


Buprenorphine Treatment for Opioid Use Disorder: An Overview. 

Shulman M, Wai JM, Nunes EV. 

CNS Drugs. 2019;33(6):567-580. doi:10.1007/s40263-019-00637-z


Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results. 

Galanter, M., Femino, J., Hunter, B. and Hauser, M. (2020), 

Am J Addict, 29: 271-278. doi:10.1111/ajad.13001


Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. 

Towers CV, Deisher H. 

Case Rep Obstet Gynecol. 2020;2020:3127676. Published 2020 Jul 17. doi:10.1155/2020/3127676

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. 

Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis

Mannheim/Lund, 29.07.2020 – Mit der wachsenden Erfahrung zum Einsatz des Depot-Buprenorphin Buvidal® seit seiner Einführung im Februar 2019 zeichnen sich die Vorteile und Chancen dieser Behandlungsform deutlicher ab. Auch durch die Coronakrise haben sich die Vergabegewohnheiten verändert. Darüber tau schten sich erfahrene Suchtmediziner*innen jüngst im Rahmen eines von der Camurus GmbH unterstützten Webinars aus. (Camurus, 29.07.2020)

Camurus Webinarbericht_final_28072020Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

Larance B, Byrne M, Lintzeris N On behalf of the CoLAB study team, et al

BMJ Open 2020;10:e034389. doi: 10.1136/bmjopen-2019-034389 

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study